A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects
Latest Information Update: 24 Nov 2025
At a glance
- Drugs Pegylated exenatide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors PegBio
Most Recent Events
- 19 Nov 2025 Status changed from active, no longer recruiting to completed.
- 11 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 28 May 2024 Status changed from not yet recruiting to recruiting.